Garuda Therapeutics, a Cambridge, MA-based hematopoietic stem cell (HSC) therapies company, raised $50M in Series A-1 funding.
Backers included OrbiMed, Northpond Ventures, Cormorant Asset Management, Kyowa Kirin Co., Ltd., a Japan-based Global Specialty Pharmaceutical Company.
Led by CEO Avanish Vellanki, Garuda develops proprietary hematopoietic stem cell (HSC) therapies that enable self-renewing, HLA compatible and transgene-free HSCs, available immediately for patients. Its technology enables self-renewing blood stem cells that are durable, human leukocyte antigen (HLA)-compatible, and transgene-free.
The company intends to use the funds for the advancement of its pipeline into the clinic, assembling an experienced team, scaling its in-house manufacturing, and other general operating activities.
FinSMEs
04/03/2025